首页工具

TRPV1 antagonist 3

产品编号 T61788

TRPV1 antagonist 3 (Compound 7q) is a highly potent antagonist of the TRPV1 receptor with an IC50 of 2.66 nM against capsaicin. It exhibits selectivity towards its mode of action and is orally bioavailable (with a bioavailability of 60%). Additionally, it can penetrate the central nervous system [1].

TargetMol的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

TRPV1 antagonist 3

TRPV1 antagonist 3, CAS N/A

规格	价格/CNY	货期
25 mg	￥ 9,870	10-14周
50 mg	￥ 13,200	10-14周
100 mg	￥ 17,500	10-14周

大包装超大折扣，点击咨询

该分子属于定制产品。陶术拥有优秀的合成团队，经验和能力，可以为您提供高性价比的产品。但由于客观因素，研发中会存在小概率合成不成功的情况，还请理解，如您有任何问题，欢迎咨询，我们将竭诚为您服务。

更多批次查询请联系客服

生物活性

化学信息

存储 & 溶解度

产品描述	TRPV1 antagonist 3 (Compound 7q) is a highly potent antagonist of the TRPV1 receptor with an IC50 of 2.66 nM against capsaicin. It exhibits selectivity towards its mode of action and is orally bioavailable (with a bioavailability of 60%). Additionally, it can penetrate the central nervous system [1].
体外活性	TRPV1 antagonist 3 (Compound 7q) is highly selective for the TRPV1 receptor relative to other TRP channels [1]. TRPV1 antagonist 3 shows acceptable aqueous solubility (solubility at pH 7.4 = 26 μg/mL) [1].
体内活性	TRPV1 antagonist 3 (Compound 7q) (0-30 mg/kg; i.p.; 30 min) shows anti-nociceptive effect mainly mediated by blocking CAP-activated channel [1]. TRPV1 antagonist 3 (0-100 mg/kg; i.g.) had no obvious thermal effect in rats [1]. TRPV1 antagonist 3 (10 mg/kg; i.v.) shows a good concentration in the brain at 0.5 h, with value of 2311 ng/g, and has good CNS penetration, with a brain/plasma ratio of 1.66 [1]. Animal Model: KM male mice (18-22 g), capsaicin, acetic acid, and thermal induced pain model [1] Dosage: 3, 10, and 30 mg/kg. 20 μL of solution of capsaicin (16 mg/20 mL) was injected s.c. under the skin of the dorsal surface of the right hind paw, or injected with 0.6% acetic acid (0.1 mL/10 g/mouse i.p.). Administration: Intraperitoneally administration; 30 min Result: In capsaicin-induced nociception, licking time decreased significantly in a dose-dependent manner. In acid-induced nociception, no significant anti-nociceptive activities were found compared with the control (SB-705498 and BCTC) at all dosage. In thermal-induced nociception, the latency time of nociceptive responses was increased at the doses of 10 and 30 mg/kg. Animal Model: Spragur-Dawley male rats (220-250 g) [1] Dosage: 10 mg/kg or 20 mg/kg Administration: Intravenous injection of 10 mg/kg or oral dose of 20 mg/kg (Pharmacokinetic Analysis) Result: In vivo pharmacokinetic parameters of TRPV1 antagonist 3 in rats (n=3) [1] Parameters IV PO t 1/2 (h) 0.106 ± 0.076 t 1/2, ka (h) 0.462 ± 0.096 t 1/2, k 10 (h) 0.527 ± 0.106 k a (1/h) 1.65 ± 0.364 k 10 (1/h) 12.076 ± 2.337 1.133 ± 0.358 V (L/kg) 0.003 ± 0.001 0.016 ± 0.006 CL (L/h/kg) 0.024 ± 0.013 0.022 ± 0.01 T max (h) 0.711 ± 0.144 C max (ng/mL) 311.377 ± 108.017 AUC 0-inf (ng/mL*h) 495.955 ± 214.634 598.873 ± 212.319 MRT (h)

分子量	391.53
分子式	C23H25N3OS

存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

计算器

摩尔浓度计算器

稀释计算器

配液计算器

分子量计算器

质量

浓度

容积

分子量

浓度 (起始)

容积 (起始)

浓度 (终)

容积 (终)

溶液体积

质量

配液浓度

剂量换算

对于不同动物的给药剂量换算，您也可以参考 更多...

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算，可以得到母液配置方法和体内配方的制备方法：比如您的给药剂量是10 mg/kg，每只动物体重20 g，给药体积100 μL，一共给药动物10 只，您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法：2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL)，如您需要配置的浓度超过该产品的溶解度，请先与我们联系。

体内配方的制备方法：取 50 μL DMSO 主液，加入 300 μL PEG300，混匀澄清，再加 50 μL Tween 80，混匀澄清，再加 600 μL ddH2O, 混匀澄清。

第一步：请输入动物实验的基本信息

剂量

mg/kg

每只动物体重

给药体积

μL

动物数量

第二步：请输入动物体内配方组成，不同的产品配方组成不同，如有配方需求，可先联系我们提供正确的体内配方。

% DMSO+

% +